Background The aim of this study was to assess the impact of bivalirudin, as compared to
unfractionated heparin, on clinical outcomes in patients with ST‐segment elevation …

In the absence of head-to-head clinical data, the objective of this study was to indirectly
compare the efficacy and safety of a bivalirudin-based anticoagulation strategy with that of …

Introduction and objectives Contrasting data have been reported on bivalirudin as an
anticoagulation strategy during percutaneous coronary interventions, offering theoretical …

Background The comparative efficacy of various anticoagulation strategies has not been
clearly established in patients with acute myocardial infarction who are undergoing …

Background The optimal anti-coagulation strategy for patients with non-ST-elevation
myocardial infarction treated with percutaneous coronary intervention is unclear in …

Background Bivalirudin is an alternative accepted therapy to unfractionated heparin for
patients with myocardial infarction (MI) undergoing percutaneous coronary intervention …

Background The aim of the study was to compare the efficacy and safety of bivalirudin
versus unfractionated heparin (UFH) in patients with acute myocardial infarction who …

Background Previous randomised trials of bivalirudin versus heparin in patients with ST-
segment elevation myocardial infarction (STEMI) undergoing primary percutaneous …

Bivalirudin, a direct thrombin inhibitor, was developed as an antithrombin agent for patients
undergoing percutaneous coronary interventions (PCI) with the hypothesis that it would …

Background Treatment with the direct thrombin inhibitor bivalirudin, as compared with
heparin plus glycoprotein IIb/IIIa inhibitors, results in similar suppression of ischemia while …